An Open-Label, Multinational, Multicenter, Phase IIIb Study With Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Docetaxel; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Roche
- 06 Mar 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 22 Dec 2018 to 31 Mar 2019.
- 05 Feb 2018 Planned End Date changed from 5 Dec 2018 to 22 Dec 2018.